Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2
Ημερομηνία
2012Συγγραφέας
Kosmidis, Paraskevas A.Syrigos, K.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Dimopoulos, M. A.
Skarlos, Dimosthenis V.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Boukovinas, I.
Bafaloukos, Dimitrios
Pectasides, Dimitrios
Bacoyiannis, Charalambos
Fountzilas, George
Source
Anticancer ResearchVolume
32Issue
1Pages
175-181Google Scholar check
Keyword(s):
Metadata
Εμφάνιση πλήρους εγγραφήςΕπιτομή
Aim: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. Patients and Methods: The patients were randomized to receive either oral vinorelbine 60 mg/m 2 on days I, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m 2 intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). Results: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6%) had a partial response (95% Cl, 0.7-18.7) and 5 (14%) had stable disease (95% CI, 4.7-29.5). In arm B, five (13%) had a partial response (95% CI, 4.4-28.1) and 7 (18%) had stable disease (95% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95% CI, 2.2-4.0) for arm A and 5.1 months (95% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). Conclusion: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases
Voulgaris, E.; Pentheroudakis, George; Pappa, L.; Bafa, M.; Goussia, Anna; Dalezis, P.; Tsombanidou, C.; Geromichalos, G.; Papageorgiou, A.; Koutsilieris, M.; Malamou-Mitsi, Vassiliki D.; Pavlidis, Nicholas (2011)Purpose: To study the phenomenon of positive urine cytology in patients with lung cancer in the absence of obvious urothelial metastases. Patients and methods: 150 patients with small (SCLC) and non-small cell lung cancer ...
-
Article
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
Briassoulis, E. Ch; Samantas, E.; Kalofonos, H. P.; Skarlos, Dimosthenis V.; Makatsoris, T.; Christodoulou, C.; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2005)The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. ...
-
Article
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peccatori, Fedro A.; Azim, Hatem A.; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas; Kesic, V.; Pentheroudakis, George (2013)